5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong

A big dividend yield only tells you what a company promises to pay. Free cash flow tells you whether it can keep paying. All five names below passed that bar last year: each one paid its dividend out of cash left over after capital spending, and the best of them, Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction), used only 39.3% of its 2025 free cash flow on the dividend. Below are the yield, the coverage math, the balance sheet and the one risk for each stock.

Philip Morris International: A Smoke-Free Cash Machine With a Fresh Raise

Philip Morris International (NYSE:PM) yields 3.14%. In 2025 it brought in $12.233 billion of operating cash flow and spent $1.569 billion on capex, which left $10.664 billion of free cash flow. Dividends cost $8.624 billion, or about 80.9% of free cash flow. That leaves a real buffer, though not a huge one.

The cash outlook is getting better. Management expects operating cash flow of around $13.5 billion this year, with capex of $1.4 to $1.6 billion and no share buybacks. Net debt is 2.35x adjusted EBITDA, and the company is aiming for about 2.0x by year-end. Stockholders’ equity is negative (-$6.7 billion), but that comes from years of buybacks and doesn’t signal a solvency problem.

The payout record backs this up. The quarterly dividend just rose to $1.60 from $1.47, and the payment history shows a higher rate every year since 2008. The finance chief called it an “unwavering commitment to our progressive dividend policy.”

Bull case: IQOS, plus ZYN after the FDA gave 20 ZYN variants its modified-risk authorization, gives the company smoke-free growth that funds future raises. Guidance for full-year adjusted EPS was lifted to $8.26 to $8.41.

Risk: The stock has risen 28.39% over the past year and now trades at 27 times trailing earnings. New buyers get less yield than they would have a year ago.

British American Tobacco: Ultra-High-Yield Income at an 11x Forward Multiple

British American Tobacco (NYSE:BTI) is the only ultra-high-yield name here, at 6.32%. Part of that yield comes from a falling share price. The ADR closed at $53.01, roughly 18.9% under its 52-week high of $65.33, and its 50-day average ($56.87) sits below its 200-day average ($58.99).

The dividend is still covered. In 2025, operating cash flow of $6.342 billion minus capex of $551 million left $5.791 billion of free cash flow. Dividends took about 88.5% of it. The full-year dividend rose 2.0% to 245.04p per share, and the quarterly ADR payment went up to $0.834851 from $0.749068. It is aiming 2.0 to 2.5x adjusted net debt to EBITDA by year-end, and it is also running a £1.3 billion buyback.

Bull case: You get a forward P/E of 11 and a growing nicotine-pouch business, with Velo Plus U.S. revenue up 310%. Guidance calls for 5% to 8% adjusted EPS growth and cash conversion above 95%.

Risk: Coverage is the lowest in this group. In the June quarter, dividends paid ($2.653 billion) were slightly higher than operating cash flow ($2.601 billion). The dividend is also set in pounds, so the dollar amount you receive moves with the exchange rate.

Kinder Morgan: Pipeline Cash Flows Paying for Growth and the Dividend

Kinder Morgan (NYSE:KMI) yields 3.8%. Even in a heavy building year it covered the payout: 2025 operating cash flow of $6.247 billion minus $3.026 billion of capex left $3.221 billion. Dividends took about 80.8% of that. Second-quarter free cash flow was $978 million and the dividend cost $665 million.

The balance sheet is getting best. Net debt is 3.6x adjusted EBITDA, at the low end of the company’s target range, and Moody’s upgraded it to Baa1. The 2026 budget sets declared dividends at $1.19 per share, up 2%. The payment record shows an increase every year since 2018.

Bull case: Kinder Morgan has a $9.6 billion project backlog. It is 92% natural gas, and more than 60% of it is linked to power generation and local gas utility demand. Adjusted EPS is running more than 12% ahead of budget.

Risk: Kinder Morgan has cut before. The quarterly payout fell from $0.51 in late 2015 to $0.125 in early 2016, so a heavy debt load and big spending plans deserve close attention.

AbbVie: Lower Yield, Wider Cushion, Steady Raises

AbbVie (NYSE:ABBV) has the lowest yield in this group at 2.6%, but its coverage is among the best. In 2025 it generated $17.816 billion of free cash flow ($19.03 billion of operating cash flow minus $1.214 billion of capex) and paid $11.657 billion in dividends. The payout ratio is about 65.4%. Net debt is 2.26x EBITDA, with interest coverage at 6.94x.

The quarterly dividend is $1.73, up from $1.64, and the record shows a higher payout every year since 2013. The trailing P/E of 75 is inflated by acquisition charges. The forward multiple is a more reasonable 16.

Bull case: Skyrizi ($5.505 billion, up 24.4%) and Rinvoq ($2.525 billion, up 24.5%) are more than making up for Humira, whose sales fell 35.9%. Total revenue grew 10.2%.

Risk: The pending $10.9 billion Apogee Therapeutics deal will be paid for with new long-term debt. The company plans to bring net leverage down to two times within two to three years following the deal close, which could slow the pace of dividend raises in the meantime.

Bristol Myers Squibb: Widest Coverage Margin in the Group

Bristol Myers Squibb yields 4.27% and has the most room to spare. In 2025, operating cash flow of $14.156 billion minus $1.311 billion of capex produced $12.845 billion of free cash flow, against $5.045 billion in dividends. The company paid down $1.2 billion of debt in the second quarter and finished it with about $11.5 billion in cash and marketable securities. Net debt is still large, at roughly $33.6 billion.

The track record is long. The $0.63 quarterly dividend is the company’s 17th consecutive annual increase and its 94th consecutive year of dividend payments. Management says it will keep “returning cash to shareholders through our commitment to the dividend.”

Bull case: The stock trades at a forward P/E of 9, and the growth portfolio now makes up nearly 60% of total revenue. Camzyos sales jumped 97% and Breyanzi rose 56% in the first quarter.

Risk: Eliquis is expected to lose U.S. exclusivity in April 2028. Milvexian, the drug meant to replace it, has had its key atrial fibrillation readout moved to the first quarter of 2027.

Coverage Separates Durable Income From Fragile Yield

All five companies paid 2025 dividends out of free cash flow, from Bristol Myers Squibb’s comfortable 39.3% to British American Tobacco’s higher 88.5%. British American Tobacco offers the most current income, and Philip Morris has the best growth story. Kinder Morgan’s pipeline backlog supports regular raises, and the two drugmakers combine wide cash buffer with long records of annual dividend increases. For the payouts to keep rising, free cash flow has to keep growing too.

Contact [email protected] for any questions or corrections.